Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome
- 31 December 2005
- journal article
- Published by Elsevier in Medical Hypotheses
- Vol. 65 (1) , 152-154
- https://doi.org/10.1016/j.mehy.2004.12.008
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology
This publication has 10 references indexed in Scilit:
- Acarbose Slows Progression of Intima-Media Thickness of the Carotid Arteries in Subjects With Impaired Glucose ToleranceStroke, 2004
- Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studiesPublished by Oxford University Press (OUP) ,2004
- Review of acarbose therapeutic strategies in the long-term treatment and in the prevention of type 2 diabetesInt. Journal of Clinical Pharmacology and Therapeutics, 2003
- Role of endothelial dysfunction in insulin resistanceThe American Journal of Cardiology, 2003
- Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients With Impaired Glucose ToleranceJAMA, 2003
- Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trialThe Lancet, 2002
- Beyond postprandial hyperglycaemia: metabolic factors associated with cardiovascular diseaseDiabetologia, 2002
- Nitric Oxide Therapies in Vascular DiseasesCurrent Pharmaceutical Design, 2002
- The role of oxidative stress in the onset and progression of diabetes and its complications: asummary of a Congress Series sponsored byUNESCO-MCBN, the American Diabetes Association and the German Diabetes SocietyDiabetes/Metabolism Research and Reviews, 2001
- The cardiovascular effects and implications of peroxynitriteCardiovascular Research, 1999